Market open
Rezolute/$RZLT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rezolute
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Ticker
$RZLT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
18
Website
Rezolute Metrics
BasicAdvanced
$272M
Market cap
-
P/E ratio
-$1.24
EPS
1.19
Beta
-
Dividend rate
Price and volume
Market cap
$272M
Beta
1.19
52-week high
$6.10
52-week low
$0.72
Average daily volume
414K
Financial strength
Current ratio
13.788
Quick ratio
13.549
Long term debt to equity
1.321
Total debt to equity
1.836
Management effectiveness
Return on assets (TTM)
-37.78%
Return on equity (TTM)
-63.88%
Valuation
Price to book
2.37
Price to tangible book (TTM)
2.37
Price to free cash flow (TTM)
-4.338
Growth
Earnings per share change (TTM)
12.56%
3-year earnings per share growth (CAGR)
-25.70%
What the Analysts think about Rezolute
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Rezolute Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Rezolute Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Rezolute News
AllArticlesVideos
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
US FDA lifts partial clinical hold on Rezolute's blood sugar treatment
Reuters·2 months ago
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rezolute stock?
Rezolute (RZLT) has a market cap of $272M as of November 22, 2024.
What is the P/E ratio for Rezolute stock?
The price to earnings (P/E) ratio for Rezolute (RZLT) stock is 0 as of November 22, 2024.
Does Rezolute stock pay dividends?
No, Rezolute (RZLT) stock does not pay dividends to its shareholders as of November 22, 2024.
When is the next Rezolute dividend payment date?
Rezolute (RZLT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rezolute?
Rezolute (RZLT) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.